Last reviewed · How we verify
PIKA COVID-19 vaccine — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
PIKA COVID-19 vaccine (PIKA COVID-19 vaccine) — Yisheng Biopharma (Singapore) Pte. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| PIKA COVID-19 vaccine TARGET | PIKA COVID-19 vaccine | Yisheng Biopharma (Singapore) Pte. Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- PIKA COVID-19 vaccine CI watch — RSS
- PIKA COVID-19 vaccine CI watch — Atom
- PIKA COVID-19 vaccine CI watch — JSON
- PIKA COVID-19 vaccine alone — RSS
Cite this brief
Drug Landscape (2026). PIKA COVID-19 vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pika-covid-19-vaccine. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab